AxonicsAnnouncing that the jury has reached a verdict in Medtronic's case at the U.S. District Court for the Central District of California againstAxonicsA unanimous decision was made in the patent infringement lawsuit. The verdict is as follows:

The jury found that:Axonics Did Not Infringe on Any of the Three Patents in the Lawsuit。

Executive Evaluation

"Our peer jury recognizes that Axonics' proprietary lead design and temperature sensor technology are different from our competitors' intellectual property. As we have said since we first filed the lawsuit at the end of 2019, we believe Medtronic's lawsuit was aimed at stifling competition, limiting patient and physician choice, and protecting the incumbent's monopoly in sacral neuromodulation. We are very pleased with the jury's decision and will continue to focus on fulfilling our mission to positively impact the lives of adults suffering from bladder and bowel dysfunction."

Since the beginning of the year, Boston Scientific andAxonicsSince reaching the final acquisition agreement to acquire Axonics at $71 per share (total price approximately $3.7 billion), Medtronic has begun its initiative againstAxonicsMore aggressive intellectual property litigation in order toBoston Scientific AcquisitionAxonicsAppropriate HandlingHuang, even if it's not yellow, we should try our best to delay the progress of Boston Scientific's acquisition.

Because at Medtronic andAxonicsIn previous competitions，AxonicsContinuously eroding Medtronic's original market, this has put immense pressure on Medtronic. NowAxonics has occupiedMore than 25% of the market,According to Raymond W. Cohen's previous estimate, within the next five years, AxThe market share of the Axonics series will reach over 50%.

Axonics R20

AxonicsLaunched the fourth-generation rechargeable implantable sacral nerve stimulator in the United States in 2023 ----Axonics R20。

Compared with the previous generations of products,Axonics R20Equipped with the function of free charging, one charge can last for 6 to 10 months (the third-generation product needs to be charged once a month).

Axonics R20Ultra-long service life--- More than 20 years (The lifespan of InterStim X is only 15 years), therefore inPatients only need to charge 1-2 times per year during the product's service life, which basically does not affect their daily lives.

Axonics R20In achieving an ultra-long lifespan while also reducing the volume, its size is only 5ml. The size of Medtronic's InterStim X is 44mm*51mm, while the size of Axonics' third-generation device is 23mm*45mm. The significant reduction in volume greatly enhances patient comfort.

Axonics R20MRIGood compatibility allows patients to undergo MRI at any time.

Axonics

AxonicsIt is a global medical device company dedicated to developing and commercializing innovative products for adults with bladder and bowel dysfunction.AxonicsRanked first in the Financial Times' 2022 list of fastest-growing companies in the Americas and second in 2023.